ImmunityBio Inc (NAS:IBRX)
$ 5.44 0.24 (4.62%) Market Cap: 3.79 Bil Enterprise Value: 4.15 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 28/100

ImmunityBio, Inc., NantKwest, Inc. - M&A Call Transcript

Dec 21, 2020 / 01:30PM GMT
Operator

Good morning, everyone. My name is Pasha, and I will be your conference operator today. Thank you for standing by, and welcome to today's call with ImmunityBio and NantKwest. (Operator Instructions) A slide presentation accompanies today's webcast and participants are invited to follow along, advancing the slides themselves. The presentation may be accessed from the Investors section of the NantKwest website. It is also available on the ImmunityBio website. After the speaker's prepared remarks, there will be a short question-and-answer session.

Please note that this event is being recorded, and I will now turn the conference over to Sarah Singleton, Manager of Investor Relations and Communications at NantKwest. Sarah, please go ahead.

Sarah Singleton

Thanks, Pasha, and thank you all for joining today's conference call to discuss the combination of ImmunityBio and NantKwest. On today's call are Dr. Patrick Soon-Shiong, Founder of ImmunityBio and NantKwest, who currently serves as CEO of ImmunityBio and Executive Chairman of NantKwest; and Rich Adcock,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot